Search results for " Sequencing"

showing 10 items of 976 documents

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing : results of the RING observational trial

2020

Plasma samples from 72 EGFR‐mutant advanced NSCLC patients, collected upon progression to first‐line TKI, were analyzed by seven methodologies (two NGS‐based methods, three high‐sensitivity PCR‐based platforms, and two FDA‐approved methods). Our study demonstrates a good to excellent agreement between methodologies and supports the use of liquid biopsies for therapy decision‐making.

0301 basic medicineOncologyMaleCancer Researchcell lung cancerIntraclass correlationBiopsyDNA Mutational Analysisnon-small cell lung cancer (NSCLC)Tyrosine kinase inhibitorTyrosine-kinase inhibitorCohort Studies*circulating free DNAT790M0302 clinical medicinetyrosine kinase inhibitorGene FrequencyOsimertinibProspective cohort studyCàncernon‐small‐cell lung cancerCirculating free DNARC254-282Research ArticlesSequence DeletionAged 80 and overNeoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-Throughput Nucleotide Sequencingnon&#8208General MedicineDNA NeoplasmExonsMiddle AgedErbB ReceptorsEpidermal growth factor receptor (EGFR) NGS Non-small cell lung cancer (NSCLC) PCR Tyrosine Kinase Inhibitor (TKI) circulating free DNA (cfDNA) osimertinibOncology030220 oncology & carcinogenesisosimertinibNGSMolecular Medicinesmall&#8208FemaleResearch Article*NGSAdultmedicine.medical_specialtymedicine.drug_classSensitivity and Specificity03 medical and health sciencesPredictive Value of TestsInternal medicineGeneticsmedicineHumansAged*non-small-cell lung cancerbusiness.industryEpidermal growth factor receptorNon invasive*epidermal growth factor receptormedicine.disease*tyrosine kinase inhibitorrespiratory tract diseases030104 developmental biologyEgfr mutationPulmonsMutationcirculating free DNAbusinessepidermal growth factor receptorNon-small-cell lung cancer*osimertinibOsimertinib
researchProduct

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy

2019

[EN] Somatic mutation analysis and evaluation of microsatellite instability (MSI) have become mandatory for selecting personalized therapy strategies for advanced colorectal cancer and are not available as routine methods in Paraguay. The aims of this study were to analyze the molecular profile as well as the microsatellite status in a series of advanced colorectal patients from two public hospitals from Paraguay, to introduce these methodologies in the routine practice to guide the therapeutic decisions. Thirty-six patients diagnosed with advanced colorectal cancer from two referent public hospitals from Paraguay were recruited from May 2017 to February 2018. Sequenom Mass spectrometry, On…

0301 basic medicineOncologyMaleCancer Researchmutational profileColorectal cancerDNA Mutational AnalysisKaplan-Meier Estimate0302 clinical medicineOriginal ResearchCancer BiologyPrecision medicineHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistryOncology030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityDisease SusceptibilityColorectal NeoplasmsAdultmedicine.medical_specialtyprecision medicinecolorectal cancerlcsh:RC254-28203 medical and health sciencesYoung AdultInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingAgedNeoplasm Stagingbusiness.industryMicrosatellite instabilityOncocartaPrecision medicinemedicine.diseaseColorectal cancerMutational profile030104 developmental biologyMutationMicrosatellite instabilityMolecular ProfileNeoplasm GradingbusinessLENGUAJES Y SISTEMAS INFORMATICOSMicrosatellite Repeats
researchProduct

A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for…

2020

AIMS Studies in various cancer types have demonstrated discordance between results from different programmed death-ligand 1 (PD-L1) assays. Here, we compare the reproducibility and analytical concordance of four clinically developed assays for assessing PD-L1-positivity in tumour-infiltrating immune cells in the tumour area (PD-L1-IC-positivity) in triple-negative breast cancer (TNBC). METHODS AND RESULTS Primary TNBC resection specimens (n = 30) were selected based on their PD-L1-IC-positivity per VENTANA SP142 ( 5%: eight cases). Serial histological sections were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3 and DAKO 28-8. PD-L1-IC-positivity and tumour cell expression (…

0301 basic medicineOncologyMalemedicine.medical_specialtyHistologyConcordanceTriple Negative Breast NeoplasmsB7-H1 AntigenPathology and Forensic MedicineCohort Studies03 medical and health sciences0302 clinical medicineBreast cancerLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorHumansTriple-negative breast cancerAgedReproducibilityWhole Genome Sequencingbusiness.industryCancerHigh-Throughput Nucleotide SequencingReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryddc:030104 developmental biology030220 oncology & carcinogenesisMutationComparison studyImmunohistochemistryFemaleNeoplasm GradingbusinessProgrammed deathHistopathologyReferences
researchProduct

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.

2019

A high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual disease (MRD) and patients are at risk of being undertreated or even overtreated with chemotherapy in this setting. Circulating-tumor DNA (ctDNA) can to be a useful tool to better detect risk of relapse.One hundred and fifty patients diagnosed with localized CC were prospectively enrolled in our study. Tumor tissue from those patients was sequenced by a custom-targeted next-generation sequencing (NGS) panel to characterize somatic mutations. A minimum varian…

0301 basic medicineOncologyMalemedicine.medical_specialtyNeoplasm ResidualColorectal cancerColonmedicine.medical_treatmentPathological stagingConcordanceDNA Mutational AnalysisKaplan-Meier EstimateAdenocarcinomaDisease-Free Survivallaw.inventionCirculating Tumor DNA03 medical and health sciences0302 clinical medicineGene FrequencylawInternal medicineBiomarkers TumorMedicineHumansDigital polymerase chain reactionPostoperative PeriodProspective StudiesPolymerase chain reactionColectomyAgedChemotherapybusiness.industryHazard ratioHigh-Throughput Nucleotide SequencingHematologymedicine.diseaseMinimal residual disease030104 developmental biologyOncology030220 oncology & carcinogenesisColonic NeoplasmsMutationFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families

2021

(1) Background: Over the last decade, genetic counseling clinics have moved from single-gene sequencing to multigene panel sequencing. Multiple genes related to a moderate risk of breast cancer (BC) have emerged, although many questions remain regarding the risks and clinical features associated with these genes. (2) Methods: Ninety-six BC index cases (ICs) with high-risk features for hereditary breast and ovarian cancer (HBOC) and with a previous uninformative result for BRCA1/2 were tested with a panel of 41 genes associated with BC risk. The frequency of pathogenic variants (PVs) was related to the clinical characteristics of BC. (3) Results: We detected a PV rate of 13.5% (excluding two…

0301 basic medicineOncologymedicine.medical_specialtyCandidate geneGenetic counselingMedicine (miscellaneous)germline testingmoderate penetrance geneshereditary breast and ovarian cancerArticle03 medical and health sciences0302 clinical medicineBreast cancerMUTYHInternal medicinemedicineCHEK2BRCA1 or BRCA2 negativebusiness.industryRBRIP1medicine.disease030104 developmental biologyMSH2030220 oncology & carcinogenesisCohortMedicinenext-generation sequencingbusinessJournal of Personalized Medicine
researchProduct

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

2017

[EN] Background: The average five-year survival for non-small cell lung cancer (NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a new class of gene regulators in humans that may play an important role in tumorigenesis. Hence, there is growing interest in studying their role as possible new biomarkers whose expression is aberrant in cancer. Therefore, in this study we identified dysregulated miRNAs by next generation sequencing (NGS) and analyzed their prognostic value. Methods: Sequencing by oligo ligation detection technology was used to identify dysregulated miRNAs in a training cohort comprising paired tumor/normal tissue samples (N = …

0301 basic medicineOncologymedicine.medical_specialtyPathologyBIOLOGIA CELULARNSCLCDNA sequencing03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerValenciaSurvival analysisbiologybusiness.industryProportional hazards modelProfilingExperimental validationbiology.organism_classificationmedicine.diseasePrognosismicroRNAsMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisNGSNon small cellPersonalized medicineprognosisprofilingbusinessResearch Paper
researchProduct

Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas.

2021

Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as “not otherwise specified” (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect t…

0301 basic medicineOncologymedicine.medical_specialtydiagnosisdiffuse large B-cell lymphomaReviewSettore MED/08 - Anatomia Patologica03 medical and health sciences0302 clinical medicineInternal medicineDaily practicemedicineTumor MicroenvironmentHumanslcsh:QH301-705.5B celltherapybusiness.industryGene Expression ProfilingNot Otherwise SpecifiedHigh-Throughput Nucleotide SequencingGeneral Medicinemedicine.diseaseMicroarray AnalysisPrognosisLymphomaGene expression profilingdiagnosi030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)Lymphoid malignancyclassification030220 oncology & carcinogenesisnext-generation sequencingLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomaprognosiCells
researchProduct

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

2019

Background Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature. Methods Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB = 0) or non-responder (non-pCR or RCB > 0) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K arra…

0301 basic medicineOncologymedicine.medical_treatmentADNlcsh:MedicineTriple Negative Breast NeoplasmsEpigenesis Genetic0302 clinical medicineGenetics (clinical)Triple-negative breast cancermedicine.diagnostic_testHigh-Throughput Nucleotide SequencingNuclear ProteinsMethylationMiddle AgedNeoadjuvant TherapyGene Expression Regulation NeoplasticTreatment OutcomeMyogenic Regulatory FactorsEfectes secundaris dels medicaments030220 oncology & carcinogenesisCohortFemaleTaxoidsMetilacióMicrotubule-Associated ProteinsAdultmedicine.medical_specialtylcsh:QH426-470MethylationMinor Histocompatibility Antigens03 medical and health sciencesBreast cancerTriple-negative breast cancerInternal medicineCell Line TumorBiopsyGeneticsmedicineHumansEpigeneticsMolecular BiologyEpigenetic signatureAgedChemotherapybusiness.industryGene Expression ProfilingResearchlcsh:RSequence Analysis DNADNADNA Methylationmedicine.diseaseHuman geneticsRepressor Proteinslcsh:Genetics030104 developmental biologyDrug side effectsbusinessPredictionDevelopmental Biology
researchProduct

A practical method for barcoding and size-trimming PCR templates for amplicon sequencing

2016

Sample barcoding facilitates the analysis of tens or even hundreds of samples in a single next-generation sequencing (NGS) run, but more efficient methods are needed for high-throughput barcoding and size-trimming of long PCR products. Here we present a two-step PCR approach for barcoding followed by pool shearing, adapter ligation, and 5′ end selection for trimming sets of DNA templates of any size. Our new trimming method offers clear benefits for phylogenetic studies, since targeting exactly the same region maximizes the alignment and enables the use of operational taxonomic unit (OTU)-based algorithms.

0301 basic medicineOperational taxonomic unitComputer science030106 microbiologyLong pcrComputational biologyPolymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyDNA sequencinglaw.invention03 medical and health scienceslawDNA Barcoding TaxonomicGenomic libraryligationPolymerase chain reactionGene Libraryta1184ta1182High-Throughput Nucleotide SequencingDNAMolecular biologyprimer030104 developmental biologyTemplatePCRpolyclonalityAmplicon sequencingTrimmingnext-generation sequencingAlgorithmsBiotechnology
researchProduct

Consequences of organ choice in describing bacterial pathogen assemblages in a rodent population

2017

SUMMARYHigh-throughput sequencing technologies now allow for rapid cost-effective surveys of multiple pathogens in many host species including rodents, but it is currently unclear if the organ chosen for screening influences the number and identity of bacteria detected. We used 16S rRNA amplicon sequencing to identify bacterial pathogens in the heart, liver, lungs, kidneys and spleen of 13 water voles (Arvicola terrestris) collected in Franche-Comté, France. We asked if bacterial pathogen assemblages within organs are similar and if all five organs are necessary to detect all of the bacteria present in an individual animal. We identified 24 bacteria representing 17 genera; average bacterial…

0301 basic medicineOperational taxonomic unitMESH: Sequence Analysis DNAEpidemiologyMESH : PrevalenceMESH : Tissue DistributionRodent DiseasesRNA Ribosomal 16Sbacterial pathogensPrevalenceMESH : DNA BacterialTissue DistributionMESH: AnimalsPathogen[SDV.EE]Life Sciences [q-bio]/Ecology environmenteducation.field_of_studybiologyEcologyArvicolinaeMicrobiotaMESH : Rodent Diseases3. Good healthMESH: RNA Ribosomal 16SInfectious DiseasesArvicolinaeFrancerodent-borne pathogenDNA Bacterial030106 microbiologyPopulationShort ReportZoology[ SDV.EE ] Life Sciences [q-bio]/Ecology environment03 medical and health sciencesAnimalsMESH: MicrobiotaMESH : BacteriaMESH: Tissue DistributionArvicola terrestriseducationMESH : FranceMESH: Prevalence[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyBacteriaHost (biology)tissue selectionBacteria PresentSequence Analysis DNAMESH: Arvicolinaebiology.organism_classificationMESH: DNA BacterialMESH: FranceMESH : ArvicolinaeMESH : RNA Ribosomal 16SMESH: BacteriaHigh-Throughput Sequencing030104 developmental biologyMESH : MicrobiotaSpecies richnessMESH: Rodent DiseasesMESH : Animals[SDE.BE]Environmental Sciences/Biodiversity and EcologyBacteriaMESH : Sequence Analysis DNA
researchProduct